The Medical Establishment is endlessly searching for quick-fix drug treatments that most of the time merely cover up symptoms. Nearly 60 percent of all Americans are currently taking a prescription medication. Equally concerning is the fact that one in five people are taking five or more prescription drugs, most of which can have serious side-effects.
There are dozens of osteoporosis medications on the market, and Savers know the dangers of these drugs. Now, a new osteoporosis treatment is on the horizon, seeking to restore normal bone structure with one single injection.
While still in the making, researchers are suggesting that a single stem cell injection could result in the development of new bone-forming cells for those who were diagnosed with osteoporosis. Although stem cell research is making great strides, currently very few stem cell treatments have been shown to be safe and effective.
Today, we’ll look at the science behind the claims, as well as the negative health effects of injectable stem cell therapy.
Recent Study Illustrates Renewal Of Bone In Mice
In a recently published Canadian study, researchers examined the effects of stem cell exposure on osteoporotic mice.1 For the study, osteoporosis-prone mice were injected with mesenchymal stem cells, or MSCs, from healthy mice.
Six months after the stem cells injection, their formerly brittle bones had been replaced with healthy bones. In fact, researchers noted that the mice had developed normal bone microarchitecture.
The study was based on previous research that showed a relationship between low bone density and low or defective MSCs in mice. The researchers postulated that if faulty MSCs were responsible for bone loss, injection of healthy MSCs should reverse it.
It’s important to note that the mice in the study had age-related osteoporosis, or secondary (Type II) osteoporosis. With this kind of osteoporosis, defects in the MSC cells cause an initial decrease in bone formation, which then causes a reduction in bone resorption, leading to low bone turnover. The researchers state that this type of therapy would not work for Type I osteoporosis, or postmenopausal osteoporosis, which is driven by increased osteoclast activity causing greater bone resorption and a high bone turnover state.
While the study authors have observed good results in mice, they suggest that ancillary studies should follow on humans. So we’ll be on the lookout for more news about future dedicated clinical trials of MSC transplantation.
What Are Mesenchymal Stem Cells (MSCs)?
Stem cells are the foundation for every organ and tissue in your body. All stem cells can self-renew, meaning that they have the ability to divide and change into different types of cells in the body. They were discovered in the early 1960s by University of Toronto professors James Till and Ernest McCulloch.
There are many different types of stem cells, and they’re from different stages in our lives and different parts of our bodies. For example, embryonic stem cells are found in the inner cell mass of early embryos. Since they can form into almost all cell lineages, they hold a lot of promise. However, many ethical concerns surround the use of embryonic stem cells.
Bone marrow from numerous species, including rodents and man, has been shown to contain a rare population of cells known as marrow stromal cells or mesenchymal stem cells (MSC).2 MSC cells, often referred to as stromal cells, have the unique ability to regenerate into various other kinds of cells, such as bone, fat, and cartilage. As they exist in almost all tissues, they can easily be isolated from several areas of the body. MSCs can be transplanted from one person to another without worry of matching the cell types and without concern of rejection.
There are currently close to 350 clinical trials occurring worldwide evaluating the potential of MSC-based cell therapy. MSCs are being evaluated for their benefit related to immune and non-immune diseases.
Dangers Of Stem Cell Treatment
While the potential of stem cell therapy may sound promising, it is a relatively new science that still requires additional research. There are some stem cell success stories, mainly related to blood stem cell transplants, such as a bone marrow transplant. Overall, however, there have been very few stem cell treatments that have been proven safe and effective.
One serious concern with stem cell transplants involves the formation of tumors. The very characteristics of MSCs that are exciting in the field of regenerative medicine are concerning in the field of oncology. While scientists generally regard the use of MSCs as safe, research is still very unclear about the role of MSCs in cancer development.3 In fact, several studies have linked MSCs to poor cancer outcomes.4,5,6
The Upside to Stem Cell Research
Bone is a dynamic tissue. In fact, did you know that your body regenerates its entire skeleton every ten years?7 It’s important to remember that bones renew themselves and that you’re not stuck with the bones you have.
One positive aspect of the current research on stem cell therapy is that it reaffirms the scientific proof that bones are active tissue and that they can regenerate themselves. The Medical Establishment has largely ignored this premise, as evidenced by the mechanism of action of commonly prescribed osteoporosis drugs. However, as the researchers note, “the osteoporotic bone had astonishingly given way to healthy, functional bone.”1 Of course, the fact that bone can renew itself is not surprising at all to Savers.
Knowing that your bones have the ability to regenerate themselves is empowering in the fight against osteoporosis. It means that it is never too late to make the necessary changes to reverse bone loss. After all, your nutrition and lifestyle choices directly influence your bone health.
At the Save Institute we are confident in the science behind the Osteoporosis Reversal Program. It is evidence-based, and more importantly, it is 100% safe, with no undesirable and dangerous side effects. Unfortunately, the same can not be said for stem cell treatments or any other osteoporosis drug at this point.
The Osteoporosis Reversal Program offers the results that Big Pharma promises, without the bone-depleting and unhealthy side effects. Quite the contrary, when you follow the Program, you’ll feel better than ever. However, just as your body did not lose bone overnight, there is no quick-fix to the problem. The Osteoporosis Reversal Program advocates a holistic approach that gets to the root of the problem and helps your body do what it knows best: to heal itself.
Stop Worrying About Your Bone Loss
Join thousands of Savers from around the world who have reversed or prevented their bone loss naturally and scientifically with the Osteoporosis Reversal Program.
Till next time,
1 Kiernan J, Hu S, Grynpas MD, Davies JE, Stanford WL. Systemic Mesenchymal Stromal Cell Transplantation Prevents Functional Bone Loss in a Mouse Model of Age-Related Osteoporosis. Stem Cells Translational Medicine.2016. 5(5). 683-693. Web: http://onlinelibrary.wiley.com/doi/10.5966/sctm.2015-0231/full
2 Short BJ, Brouard N, Simmons PJ, Audet J, Stanford WL. Prospective isolation of mesenchymal stem cells from mouse compact bone. Stem Cells in Regenerative Medicine. Totowa, NJ: Humana Press, 2009:259–268. Web: https://link.springer.com/protocol/10.1007%2F978-1-59745-060-7_16
3 Farida D, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 2003. ;102(10):3837-44. Web: https://www.ncbi.nlm.nih.gov/pubmed/12881305
4 Kansy BA, et al. The bidirectional tumor–mesenchymal stromal cell interaction promotes the progression of head and neck cancer. Stem Cell Res Ther. 2014;5(4):95.
5 Karnoub AE, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63. Web: http://www.nature.com/nature/journal/v449/n7162/full/nature06188.html
6 Prantl L, et al. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate. 2010;70(15):1709–15.
7 Manolagas SC, Parfitt AM. What old means to bone. Trends Endocrinol Metab. 2010;21:369–374.